On January 5, 2022, Zymeworks Inc. announced that the Company's board of directors appointed Mr. Kenneth Galbraith as President and Chair of the Board of the Company, effective upon his commencement of employment with the Company, which is anticipated to be on or before February 1, 2022. In connection with Mr. Galbraith's appointment, Dr. Ali Tehrani resigned from the positions of President and as a member of the Board, effective as of the Start Date. The Board also appointed Ms. Lota Zoth, the current Chair of the Board, as the Board's lead independent director, effective as of the Start Date.

Mr. Galbraith is a Managing Director at Five Corners Capital Inc. and has served as Executive in Residence at Syncona Limited since April 2021. He served as Chief Executive Officer of Liminal BioSciences Inc. (formerly Prometic Life Sciences Inc.). On January 5, 2022, the Company announced that the Board appointed Mr. Neil Klompas, as Chief Operating Officer, effective January 5, 2022.

Mr. Klompas currently serves as the Company's Executive Vice President, Business Operations and Chief Financial Officer, and will continue in the role of Chief Financial Officer following his appointment as Chief Operating Officer.